Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

$17995

This report covers the 7 major markets and provides an Excel-based forecast model for the Idiopathic Pulmonary Fibrosis (IPF) market through 2034.

GlobalData estimated that drug sales for IPF in 2024 were approximately $2.7 billion across the 7MM, with the market size anticipated to grow to approximately $5.8 billion by 2034, at a compound annual growth rate (CAGR) of 7.7%.

Major drivers of growth during the forecast period include the launches of several pipeline agents, most notably Jascayd (nerandomilast), Tyvaso (treprostinil), and admilparant, the increase in the number of diagnosed prevalent cases of IPF throughout the 7MM, the increase in the use of combination therapy and the number of patients on disease-modifying therapies.

Scope

Overview of Idiopathic Pulmonary Fibrosis (IPF), including epidemiology, symptoms, diagnosis, and disease management.

Annualized IPFtherapeutics market revenue, cost of therapy per patient, and treatment usage patterns forecast from 2024 to 2034.

Key topics covered include strategic competitor assessment, market characterization, unmet needs, clinical trial mapping, and implications of these factors for the IPF therapeutics market.

Pipeline analysis: comprehensive data assessing emerging trends and mechanisms of action under development for IPF treatment. The most promising candidates in late-stage development are profiled.

Analysis of the current and future market competition in the global IPF therapeutics market. Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide qualitative analysis of its implications.

Reasons to Buy

Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.

Develop business strategies by understanding the trends shaping and driving the 7MM IPF therapeutics market.

Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the 7MM IPF therapeutics market in the future.

Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

Amgen
Bristol-Myers Squibb
Eli Lilly
United Therapeutics
Horizon Therapeutics
Vicore Pharma
Palisade Bio
EmphyCorp
Boehringer Ingelheim
InSilico Medicine
PureTech
Roche
Mediar Therapeutics
Qureight
Endeavor BioMedicines
Transpire Bio
Suzhou Intragrand Pharma

Table of Contents

List of Contents

List of Tables

List of Figures

1 Idiopathic Pulmonary Fibrosis: Executive Summary

1.1 IPF market to increase slightly from 2024–34

1.2 Innovative small pharma companies require partnerships to successfully commercialize clinical pipeline

1.3 High unmet clinical needs remain for more effective drugs with cleaner safety profiles

1.4 Late-stage pipeline span across different mechanisms of action

1.5 What do physicians think?

2 Introduction

2.1 Catalyst

2.2 Related reports

2.3 Upcoming reports

3 Disease Overview

3.1 Etiology and pathophysiology

3.1.1 Genetic factors

3.1.2 Environmental factors

3.1.3 Pathophysiology

3.2 Classification or staging systems

3.2.1 GAP model

3.2.2 Stratification by decline in FVC

4 Epidemiology

4.1 Disease background

4.2 Risk factors and comorbidities

4.3 Global and historical trends

4.4 7MM forecast methodology

4.4.1 Sources

4.4.2 Forecast assumptions and methods

4.4.3 Forecast assumptions and methods: diagnosed prevalent cases of IPF

4.5 Epidemiological forecast for IPF (2024–34)

4.5.1 Diagnosed prevalent cases of IPF

4.5.2 Age-specific diagnosed prevalent cases of IPF

4.5.3 Sex-specific diagnosed prevalent cases of IPF

4.6 Discussion

4.6.1 Epidemiological forecast insight

4.6.2 Limitations of the analysis

4.6.3 Strengths of the analysis

5 Disease Management

5.1 Diagnosis and treatment overview

6 Current Treatment Options

6.1 Overview

6.2 Symptomatic treatments

7 Unmet Needs and Opportunity Assessment

7.1 Overview

7.2 Therapies that reverse progression

7.3 Improved drug safety, tolerability, and side effects

7.4 Treatments for patients with severe disease

8 R&D Strategies

8.1 Overview

8.1.1 Regulatory designations

8.1.2 Sponsor activity

8.1.3 Combination therapy

8.1.4 Clinical trials design

8.1.5 Increased use of quality-of-life measures

9 Pipeline Assessment

9.1 Overview

9.2 Innovative drugs in clinical development

9.3 In-class improvement and symptomatic treatment

10 Pipeline Valuation Analysis

10.1 Overview

10.2 Competitive assessment

11 Current and Future Players

11.1 Overview

11.2 Deal-making trends

11.2.1 Partnerships, licensing agreements and mergers and acquisitions in IPF

12 Market Outlook

12.1 Global markets

12.1.1 Forecast

12.1.2 Drivers and barriers – global issues

12.2 US

12.2.1 Forecast

12.2.2 Key events

12.2.3 Drivers and barriers

12.3 5EU

12.3.1 Forecast

12.3.2 Key events

12.3.3 Drivers and barriers

12.4 Japan

12.4.1 Forecast

12.4.2 Key events

12.4.3 Drivers and barriers

13 Appendix

13.1 Bibliography

13.2 Abbreviations

13.3 Methodology

13.3.1 Forecasting Methodology

13.4 Primary Research – KOLs and Payers Interviewed for This Report

13.4.1 KOLs

13.5 Primary Research – Prescriber Survey

13.6 About the Authors

13.6.1 Analyst

13.6.2 Associate Director

13.6.3 Therapy Area Director

13.6.4 Epidemiologist

13.6.5 Managing Epidemiologists

13.6.6 Vice President of Disease Analysis and Intelligence

13.6.7 Global Head of Pharma Research, Analysis, and Competitive Intelligence

About GlobalData

Contact Us

Table

Table 1: IPF: Key metrics in the 7MM

Table 2: The GAP index

Table 3: Risk factors and comorbidities for IPF

Table 4: Overview of IPF treatment guidelines

Table 5: Leading treatments for IPF, 2025

Table 6: Most commonly prescribed symptomatic treatments for IPF

Table 7: Top 10 deals by value, 2023–25

Table 8: IPF market – global drivers and barriers, 2024–34

Table 9: Key events impacting sales for IPF in the US, 2024–34

Table 10: IPF market – drivers and barriers in the US, 2024–34

Table 11: Key events impacting sales for IPF in the 5EU, 2024–34

Table 12: IPF market – drivers and barriers in the 5EU, 2024–34

Table 13: Key events impacting sales for IPF in Japan, 2024–34

Table 14: IPF market – drivers and barriers in Japan, 2024–34

Table 15: High-prescribing physicians (non-KOLs) surveyed, by country

Figures

Figure 1: Global sales forecast by country for IPF in 2024 and 2034

Figure 2: Competitive assessment of the marketed and pipeline systemic drugs benchmarked against the SOCs, Esbriet and Ofev

Figure 3: The induction and progression of IPF

Figure 4: 7MM, diagnosed prevalence of IPF (%), both sexes, ages ≥18 years, 2024

Figure 5: 7MM, sources used and not used to forecast the diagnosed prevalent cases of IPF

Figure 6: 7MM, diagnosed prevalent cases of IPF, N, both sexes, ages ≥18 years, 2024

Figure 7: 7MM, diagnosed prevalent cases of IPF by age, N, both sexes, 2024

Figure 8: 7MM, diagnosed prevalent cases of IPF by sex, N, ages ≥18 years, 2024

Figure 9: Flowchart of the diagnosis and management of IPF

Figure 10: Unmet needs and opportunities in IPF

Figure 11: Overview of the development pipeline in IPF

Figure 12: Key late-stage trials for promising agents that GlobalData expects to be licensed for IPF in the 7MM during the forecast period

Figure 13: Competitive assessment of marketed and pipeline systemic drugs benchmarked against the SOC, Ofev and Esbriet

Figure 14: Analysis of the company portfolio gap in IPF during the forecast period, 2024–34

Figure 15: Global (7MM) sales forecast by country for IPF in 2024 and 2034

Figure 16: Global (7MM) sales forecast by drug for IPF in 2024 and 2034

Figure 17: Sales forecast by class for IPF in the US in 2024 and 2034

Figure 18: Sales forecast by class for IPF in the 5EU in 2024 and 2034

Figure 19: Sales forecast by class for IPF in Japan in 2024 and 2034

Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 standard reports
Currency USD
$17,995

Can be used by individual purchaser only

$53,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

See what our customers are saying
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image
testimonial-image

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 in real time.

  • Access a live Idiopathic Pulmonary Fibrosis (IPF) Major Markets, Disease Management, Epidemiology, Pipeline Assessment, Unmet Needs and Drug Forecast to 2034 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.